The impact of left ventricular assist device-induced left ventricular unloading on the myocardial renin-angiotensin-aldosterone system: Therapeutic consequences?

European Heart Journal

Volumn 30, Issue 7, 2009, Pages 805-812

  Klotz, Stefan ^a   Burkhoff, Daniel ^b   Garrelds, Ingrid M ^c   Boomsma, Frans ^c   Danser, A H Jan ^c  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^b Columbia University ^*  (United States)

^c ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Catecholamine; Collagen; Heart failure; Left ventricular assist device; Renin angiotensin aldosterone system; Reverse remodelling

Indexed keywords

ADRENALIN; ALDOSTERONE; ANGIOTENSIN II; ANGIOTENSINOGEN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FUROSEMIDE; INOTROPIC AGENT; MINERALOCORTICOID RECEPTOR; NORADRENALIN; RENIN;

ADOLESCENT; ADRENERGIC SYSTEM; ADULT; AGED; ARTICLE; BLOOD PRESSURE; CARDIOMYOPATHY; CLINICAL ARTICLE; CLINICAL FEATURE; CONGESTIVE CARDIOMYOPATHY; CONTROLLED STUDY; CONVALESCENCE; FEMALE; HEART FAILURE; HEART LEFT VENTRICLE; HEART MUSCLE; HEART MUSCLE ISCHEMIA; HUMAN; HUMAN TISSUE; IMPLANT; ISCHEMIC CARDIOMYOPATHY; ISCHEMIC HEART DISEASE; LEFT VENTRICLE ASSIST DEVICE; MALE; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; TISSUE LEVEL;

ADOLESCENT; ADULT; AGED; ALDOSTERONE; BLOOD PRESSURE; FEMALE; HEART FAILURE; HEART TRANSPLANTATION; HEART-ASSIST DEVICES; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL ISCHEMIA; MYOCARDIUM; NOREPINEPHRINE; RENIN; RENIN-ANGIOTENSIN SYSTEM; TREATMENT OUTCOME; VENTRICULAR FUNCTION, LEFT; YOUNG ADULT;

EID: 64849107987     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehp012     Document Type: Article

References (52)

1. Stewart S. Prognosis of patients with heart failure compared with common types of cancer. Heart Fail Monit 2003:3:87-94.
2. Rose EA, Gelijns AC, Moskowitz AJ, Heltjan DF, Stevenson LW, Dembitsky W, Long JW, Aschelm DD, Tierney AR, Levitan RG, Watson JT, Meier P, Ronan NS, Shapiro PA, Lazar RM, Miller LW, Gupta L Frazier OH, Desvigne-Nickens P, Oz MC, Poirier VL. Long-term mechanical left ventricular assistance for end-stage heart failure. N Engl J Med 2001:345:1435-1443.
3. Levin HR, Oz MC, Chen JM, Packer M, Rose EA, Burkhoff D. Reversal of chronic ventricular dilation in patients with end-stage cardiomyopathy by prolonged mechanical unloading. Circulation 1995:91:2717-2720.
4. Nishimura M, Radovancevic B, Odegaard P, Myers T, Springer W, Frazier OH. Exercise capacity recovers slowly but fully in patients with a left ventricular assist device. ASAIO J 1996;42:M568-M570.
5. Birks EJ, Tansley PD, Hardy J, George RS, Bowles CT, Burke M, Banner NR, Khaghani A, Yacoub MH. Left ventricular assist device and drug therapy for the reversal of heart failure. N Engl J Med 2006;355:1873-1884.
6. Burkhoff D, Klotz S, Mancini DM. LVAD-lnduced reverse remodeling: basic and clinical implications for myocardial recovery. J Card Fail 2006:12:227-239.
7. Ljden H, Karason K, Bergh CH, Nilsson F, Koul B, Wiklund L The feasibility of left ventricular mechanical support as a bridge to cardiac recovery. Eur J Heart Fail 2007:9:525-530.
8. Maybaum S, Mancini D, Xydas S, Starling RC, Aaronson K, Pagani FD, Miller LW, Margulies K, McRee S, Frazier OH, Torre-Amione G. Cardiac improvement during mechanical circulatory support: a prospective multicenter study of the LVAD Working Group. Circulation 2007;115:2497-2505.
9. Simon MA, Kormos RL, Gorcsan J III, Dohl K, Winowich S, Stanford E, Carozza L Murali S. Differential exercise performance on ventricular assist device support. J Heart Lung Transplant 2005;24:1506-1512.
10. George I, Xydas S, Mancini DM, Lamanca J, DiTullio M, Marboe CC, Shane E, Schulman AR, Colley PM, Petrilli CM, Naka Y, Oz MC, Maybaum S. Effect of clenbuterol on cardiac and skeletal muscle function during left ventricular assist device support. J Heart Lung Transplant 2006;25:1084-1090.
11. Klotz S, Foronjy RF, Dickstein ML, Gu A, Garrelds IM, Danser AHJ, Oz MC, D'Armiento J, Burkhoff D. Mechanical unloading during left ventricular assist device support increases left ventricular collagen cross-linking and myocardial stiffness. Circulation 2005:112:364-374.
12. Klotz S, Danser AHJ, Foronjy RF, Oz MC, Wang J, Mancini D, D'Armiento J, Burkhoff D. The impact of angiotensin-converting enzyme inhibitor therapy on the extracellular collagen matrix during left ventricular assist device support in patients with end-stage heart failure. J Am Coll Cardiol 2007:49:1166-1174.
13. Danser AHJ, van Kesteren CAM, Bax WA, Tavenier M, Derkx FHM, Saxena PR, Schalekamp MADH, Prorenin, renin, angiotensinogen, and angiotensin-converting enzyme in normal and falling human hearts. Evidence for renin binding. Circulation 1997:96:220-226.
14. Chai W, Garrelds IM, de Vries R, Batenburg WW, van Kats JP, Danser AHJ. Non-genomic effects of aldosterone in the human heart. Interaction with angiotensin II. Hypertension 2005:46:701-706.
15. van der Hoorn FA, Boomsma F, Man in t Veld AJ, Schalekamp MA. Determination of catecholamines in human plasma by high-performance liquid chromatography: comparison between a new method with fluorescence detection and an established method with electrochemical detection. J Chromatogr 1989;487:17-28.
16. Anversa P, Lerl A, Li B, Liu Y, Di Somma S, Kajstura J. Ischemic cardiomyopathy and the cellular renin-angiotensin system. J Heart Lung Transplant 2000;19: S1-S11.
17. Geronikaki A, Gavalas A, Dislian V, Giannoglou G. Inhibition of renin-angiotensin system and advanced glycation end products formation: a promising therapeutic approach targeting on cardiovascular diseases. Cardiovasc Hematol Agents Med Chem 2007;5:249-264.
18. Brugts JJ, Boersma E, Chonchol M, Deckers JW, Bertrand M, Remme WJ, Ferrari R, Fox K, Simoons ML. The cardioprotective effects of the angiotensin-converting enzyme inhibitor perindopril in patients with stable corona7 artery disease are not modified by mild to moderate renal insufficiency: insights from the EUROPA trial. J Am Coll Cardiol 2007;50:2148- 2155.
19. van Kats JP, Danser AHJ, van Meegen JR, Sassen LM, Verdouw PD, Schalekamp MADH. Angiotensin production by the heart: a quantitative study in pigs with the use of radiolabeled angiotensin infusions. Circulation 1998;98: 73-81.
20. van Kats JP, Duncker DJ, Haitsma DB, Schuijt MP, Niebuur R, Stubenitsky R, Boomsma F, Schalekamp MADH, Verdouw PD, Danser AHJ. Angiotenslnconverting enzyme inhibition and angiotensin II type 1 receptor blockade prevent cardiac remodeling in pigs after myocardial infarction: role of tissue angiotensin II. Circulation 2000:102:1556-1563.
21. Danser AHJ. Local renin-angiotensin systems: the unanswered questions. Int J Biochem Cell Biol 2003;35:759-768.
22. Danser AHJ, van Kats JP, Admiraal PJJ, Derkx FHM, Lamers JMJ, Verdouw PD, Saxena PR, Schalekamp MADH. Cardiac renin and angiotensins. Uptake from plasma versus in situ synthesis. Hypertension 1994;24:37-48.
23. de Lannoy LM, Danser AHJ, van Kats JP, Schoemaker RG, Saxena PR, Schalekamp MADH. Renin-angiotensin system components in the interstitial fluid of the isolated perfused rat heart. Local production of angiotensin I. Hypertension 1997;29:1240-1251.
24. Katz SA, Opsahl JA, Lunzer MM, Forbis LM, Hirsch AT. Effect of bilateral nephrectomy on active renin, angiotensinogen, and renin glycoforms in plasma and myocardium. Hypertension 1997;30:259-266.
25. Studer R, Relnecke H, Muller B, Holtz J, Just H, Drexler H. Increased angiotensin-l converting enzyme gene expression in the failing human heart Quantification by competitive RNA polymerase chain reaction. J Clin Invest 1994;94:301-310.
26. Batenburg WW, Garrelds IM, Bernasconi CC, Juillerat-Jeanneret L, van Kats JP, Saxena PR, Danser AHJ. Angiotensin II type 2 receptor-mediated vasodilation in human coronary microarteries. Circulation 2004;109:2296-2301.
27. Danser AHJ, Deinum J. Renin, prorenin and the putative (pro)renin receptor. Hypertension 2005;46:1069-1076.
28. Huang Y, Wongamorntham S, Kasting J, McQuillan D, Owens RT, Yu L Noble NA, Border W. Renin increases mesangial cell transforming growth factor-beta1 and matrix proteins through receptor-mediated, angiotensin lI- independent mechanisms. Kidney Int 2006;69:105-113.
29. Nguyen G, Delarue F, Burcklé C, Bouzhir L, Glller T, Sraer J-D. Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin.J Clin Invest 2002;109:1417-1427.
30. Batenburg WW, Krop M, Garrelds IM, de Vries R, de Bruin RJA, Burcklé C, Müller DN, Bader M, Nguyen G, Danser AHJ. Prorenin is the endogenous agonist of the (pro)renin receptor. Binding kinetics of renin and prorenin in rat vascular smooth muscle cells overexpressing the human (pro)renin receptor. J Hypertens 2007:25:2441-2453.
31. Saris JJ, 't Hoen PAC, Garrelds IM, Dekkers DHW, den Dunnen JT, Lamers JMJ, Danser AHJ, Prorenin induces Intracellular signalling in cardiomyocytes independently of angiotensin II. Hypertension 2006;48:564-571.
32. Silvestre JS, Robert V, Heymes C, Aupetit-Faisant B, Mouas C, Moalic JM, Swynghedauw B, Delcayre C. Myocardial production of aldosterone and corticosterone in the rat Physiological regulation. J Biol Chem 1998;273:4883-4891.
33. Chai W, Garrelds IM, de Vries R, Danser AHJ. Cardioprotective effects of eplerenone in the rat heart: interaction with locally synthesized or blood-derived aldosterone? Hypertension 2006;47:665-670.
34. Gomez-Sanchez EP, Ahmad N, Romero DG, Gomez-Sanchez CE. Origin of aldosterone in the rat heart. Endocrinology 2004;145:4796-4802.
35. 2 in peripheral blood mononuclear cells. Circulation 2005;111:51-57.
36. Chai W, Hoedemaekers Y, van Schaik RH, van Fessem M, Garrelds IM, Saris JJ, Dooijes D, ten Cate FJ, Kofflard MM, Danser AH. Cardiac aldosterone in subjects with hypertrophic cardiomyopathy. J Renin Angiotensin Aldosterone Syst 2006;7: 225-230.
37. Ouvrard-Pascaud A, Sainte-Marie Y, Benitah JP, Perrier R, Soukaseum C, Cat AN, Royer A, Le Quang K, Charpentier F, Demolombe S, Mechta-Grigoriou F, Beggah AT, Maison-Blanche P, Oblin ME, Delcayre C, Fishman GI, Farman N, Escoubet B, Jaisser F. Conditional mineralocorticoid receptor expression in the heart leads to life-threatening arrhythmias. Circulation 2005;111:3025-3033.
38. Madigan JD, Barbone A, Choudhri AF, Morales DL, Cai B, Oz MC, Burkhoff D. Time course of reverse remodeling of the left ventricle during support with a left ventricular assist device. J Thorac Cardiovasc Surg 2001;121:902-908.
39. Heller LJ, Opsahl JA, Wernsing SE, Saxena R, Katz SA. Myocardial and plasma renin-angiotensinogen dynamics during pressure-induced cardiac hypertrophy. Am J Physiol 1998;274:R849-R856.
40. Naseem RH, Hedegard W, Henry TD, Lessard J, Sutter K, Katz SA. Plasma cathepsin D isoforms and their active metabolites increase after myocardial infarction and contribute to plasma renin activity. Basic Res Cardiol 2005;100: 139-146.
41. Danser AHJ, Derkx FHM, Schalekamp MADH, Hense HW, Riegger GAJ, Schunkert H. Determinants of interindividual variation of renin and prorenin concentrations: evidence for a sexual dimorphism of (pro)renin levels in humans. J Hypertens 1998;16:853-862.
42. Campbell DJ, Kladis A, Duncan AM. Effects of converting enzyme inhibitors on angiotensin and bradykinin peptides. Hypertension 1994;23:439-449.
43. Griffiths CD, Morgan TO, Delbridge LM. Effects of combined administration of ACE inhibitor and angiotensin II receptor antagonist are prevented by a high NaCl intake. J Hypertens 2001;19:2087-2095.
44. Jorde UP, Vittorio T, Katz SD, Colombo PC, Latif F, Le Jemtel TH. Elevated plasma aldosterone levels despite complete inhibition of the vascular angiotensinconverting enzyme in chronic heart failure. Circulation 2002;106:1055-1057.
45. Fiebeler A, Nussberger J, Shagdarsuren E, Rong S, Hilfenhaus G, Al-Saadi N, Dechend R, Wellner M, Meiners S, Maser-Gluth C, Jeng AY, Webb RL, Luft FC, Müller DN. Aldosterone synthase inhibitor ameliorates angiotensin II-induced organ damage. Circulation 2005;111:3087-3094.
46. Saino A, Pomidossi G, Perondi R, Morganti A, Turolo L, Mancia G. Modulation of sympathetic coronary vasoconstriction by cardiac renin-angiotensin system in human coronary heart disease. Circulation 2000;101: 2277-2283.
47. Batenburg WW, van Esch JHM, Garrelds IM, Jorde U, Lamers JM, Dekkers DH, Walther T, Kellett E, Milligan G, van Kats JP, Danser AHJ. Carvedilol-induced antagonism of angiotensin II: a matter of alpha1-adrenoceptor blockade. J Hypertens 2006;24:1355-1363.
48. Bonnefont-Rousselot D, Mahmoudi A, Mougenot N, Varoquaux O, Le Nahour G, Fouret P, Lechat P. Catecholamine effects on cardiac remodelling, oxidative stress and fibrosis in experimental heart failure. Redox Rep 2002;7:145-151.
49. Briest W, Holzl A, Rassler B, Deten A, Leicht M, Baba HA, Zimmer HG. Cardiac remodeling after long term norepinephrine treatment in rats. Cardiovasc Res 2001; 52:265-273.
50. Bruggink AH, van Oosterhout MF, de Jonge N, Ivangh B, van Kuik J, Voorbij RH, Cleutjens JP, Gmelig-Meyling FH, de Weger RA. Reverse remodeling of the myocardial extracellular matrix after prolonged left ventricular assist device support follows a biphasic pattern. J Heart Lung Transplant 2006;25:1091-1098.
51. Liang H, Muller J, Weng YG, Wallukat G, Fu P, Lin HS, Bartel S, Knosalla C, Pregla R, Hetzer R. Changes in myocardial collagen content before and after left ventricular assist device application in dilated cardiomyopathy. Chin Med J (Engl) 2004;117:401-407.
52. Matsumiya G, Monta O, Fukushima N, Sawa Y, Funatsu T, Toda K, Matsuda H. Who would be a candidate for bridge to recovery during prolonged mechanical left ventricular support in idiopathic dilated cardiomyopathy? J Thorac Cardiovasc Surg 2005;130:699-704.